Injectable PDRN,
does it really help with Increased complete closure of chronic diabetic foot ulcers by eight weeks?
research showsThe grade is C. A double-blind trial randomized 216 participants, 110 to PDRN and 106 to placebo, and 192 completed, 101/91. Intention-to-treat healing using randomized denominators was 41/110 (37.3%, 95% CI 28.2 to 46.3) versus 20/106 (18.9%, 11.4 to 26.3), P=0.0027, with healing HR 2.20 (95% CI 1.29 to 3.75). One manufacturer-supported confirmatory trial gives C with 54 points.
ads claimThis was injectable PDRN added to standard wound care. The result cannot be transferred to oral products, cosmetics, joint injections, or every chronic wound merely because they share the PDRN name.
Useful facts when choosing a product
- The trial used a Mastelli Placentex-type formulation containing 5.625 mg PDRN per 3 mL, given intramuscularly five days per week and perilesionally two days per week for eight weeks.
- Participants had selected Wagner grade 1 or 2 ulcers without gangrene or untreated infection and with transcutaneous oxygen pressure above 29 mmHg.
- Verdict 588 is ? for oral PDRN and skin rejuvenation, while verdict 1907 is C with 46 points for knee injections; route and indication differ.
Chamgap Semantic Classification Code
Candidate index · review held
M.injectable-polydeoxyribonucleotide.UNK.complete-closure-of-chronic-diabetic-foot-ulcers-by.increase.placeboMedicinal interventions > Injectable polydeoxyribonucleotide > Unknown > complete closure of chronic diabetic foot ulcers by > Increase claim > Placebo
An automated migration candidate, not an issued permanent code; exact claim scope remains under review. This machine-generated migration candidate helps retrieval but is not a permanent assignment. The original verdict ID and URL remain authoritative.
What the research actually shows
Squadrito randomized 216 participants, 110 to PDRN and 106 to placebo, and 192 completed, 101/91. Healing percentages used randomized denominators in the intention-to-treat result: 37.3% versus 18.9%, HR 2.20 (95% CI 1.29 to 3.75), with median healing time 30 days for PDRN versus 49 for placebo. Mastelli supplied funding and product, and no large nonmanufacturer confirmatory trial of complete healing was identified. A small 2018 Korean trial assessed short-term tissue oxygenation and angiogenesis, not the same confirmatory endpoint. Verdict 1933 is B with 76 points for total contact casting in the same indication, where complete healing was replicated by two different small trials.
Why this is classified as C (54)
Complete closure improved by 18.4 points, but the manufacturer-supported evidence is a single short trial, giving C with 54 points.
Counterpoint. Independent long-term replication with recurrence and amputation outcomes is needed.
Rejudgment record. Cross-check applied — A double-blind 216-participant trial showed a large closure benefit, but it was a single eight-week manufacturer-supported confirmation without independent replication
| Endpoint | H | Hard endpoint - actual events such as death |
| Replication | R1 | Single confirmatory trial |
| Independence | I0 | Evidence comes only from manufacturer studies |
| Effect size | E+ | Meets the clinically important threshold |
Stored derived and displayed grades match; this is not a current recalculation or validity check (C).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Increased complete healing at eight weeks | C | Rates were 37.3% versus 18.9%, but evidence comes from one product-linked trial. |
| Shorter time to healing | C | Median time was 30 versus 49 days. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Squadrito et al. 2014 | Two-center randomized double-blind placebo-controlled trial | 216 randomized, 110 PDRN and 106 placebo; 192 completed, 101/91; ITT percentages used randomized denominators | Departmental funding plus Mastelli support and study-drug supply | Complete healing at eight weeks and time to healing | 41/110 (37.3%, 95% CI 28.2 to 46.3) versus 20/106 (18.9%, 11.4 to 26.3), P=0.0027; HR 2.20 (1.29 to 3.75); median 30 versus 49 days | Only product-linked confirmatory trial |
Receipt — 1 References
All 1 cited sources were verified for existence at the original page (as of 2026-08-01).
Final verification and publication gate: Codex · Evidence date: 2026-08-01 · Corrections: none
Cite this verdict
[Chamgap] Injectable PDRN x complete healing of diabetic foot ulcers — Evidence Grade C·54. 1 cited sources checked. Source: https://chamgap.com/en/verdicts/blood-sugar/injectable-pdrn-diabetic-foot-ulcer-complete-healing/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.